Myasthenia gravis inebilizumab trial mint
WebMyasthenia Gravis INebilizumab Trial (MINT) A.4.1: Sponsor's protocol code number: VIB0551.P3.S1: A.7: Trial is part of a Paediatric Investigation Plan: No : A.8: ... - Change in Myasthenia Gravis Quality of Life-15, revised (MGQOL-15r) score . - Change in Patient Global Impression of Change (PGIC) score. WebThe primary objective of this study is to evaluate the efficacy of eculizumab in the treatment of pediatric refractory generalized myasthenia gravis (gMG) based on change from Baseline in the Quantitative Myasthenia Gravis score for disease severity (QMG). Sponsor: Alexion Pharmaceuticals ClinicalTrials.gov page: Alexion.com
Myasthenia gravis inebilizumab trial mint
Did you know?
WebDetails. This study is a phase 3, randomized, double-blind, placebo-controlled study, to be conducted at approximately 100 study sites. Approximately 252 subjects (172 AChR-Ab+ and 80 MuSK-Ab+) will be enrolled. Patients with MG who are positive for anti-AChR or anti-MuSK antibodies will be enrolled and analyzed separately as 2 populations: (1 ... WebMyasthenia Gravis Inebilizumab Trial (MINT) Latest version (submitted October 18, 2024) on ClinicalTrials.gov A study version is represented by a row in the table. Select two study versions to compare. One each from columns A and B.
WebApr 1, 2024 · Myasthenia Gravis Inebilizumab Trial (MINT) Conditions Diseases of the Nervous System Phase III Volunteers Health Professionals What is the purpose of this … WebApr 4, 2024 · The Myasthenia gravis Inebilizumab Trial (MINT) study is a randomized placebo-controlled trial of intravenous inebilizumab (300 mg given on Day 1, 15 and 183) …
WebNote: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about … WebThe Myasthenia gravis Inebilizumab Trial (MINT) study is a randomized placebo-controlled trial of intravenous inebilizumab (300 mg given on Day 1, 15 and 183) in antibody positive (either anti AChR or MuSK antibody) gMG as an add-on therapy. Bortezomib.
WebApr 11, 2024 · A Randomized, Double-blind, Multicenter, Placebo-controlled Phase 3 Study With Open-label Period to Evaluate the Efficacy and Safety of Inebilizumab in Adults With …
WebDetails. This study is a phase 3, randomized, double-blind, placebo-controlled study, to be conducted at approximately 100 study sites. Approximately 252 subjects (172 AChR-Ab+ … does wesley snipes have cancerhttp://www.mgakc.org/clinical-trials.html does west 216 connect to another room tarkovWebMar 24, 2024 · Inebilizumab is a humanised afucosylated immunoglobulin G 1 kappa (IgG1κ) ... Myasthenia gravis; Systemic scleroderma ... 14 Mar 2024 Updated efficacy data from a phase II/III trial in Neuromyelitis optica released by Horizon Therapeutics ; … factory team rc toolsWebThe myasthenia gravis inebilizumab trial (MINT): design of randomized, placebocontrolled phase 3 study of an anti-CD19 monoclonal antibody in generalized myasthenia gravis does wesley die in the princess brideWebJul 27, 2024 · A clinical trial to look at how safe and effective satralizumab is at reducing certain signs of generalised myasthenia gravis (gMG) A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis Myasthenia Gravis (IAB) Trial Status: Recruiting This trial runs in does weslo treadmill have inclineWebNov 24, 2016 · We have demonstrated that inebilizumab administration in hCD19 Tg mice leads to dose-dependent depletion of B cells in blood and lymphoid tissues: after a 1-week treatment with inebilizumab at doses of ≥0.5 mg/kg, more than 90% of B cells in spleen, bone marrow, and blood were depleted [ 48 ]. factory techWebTake the first step in your myasthenia gravis (MG) care and find out if MINT is right for you. How could participating in the MINT study help further the knowledge of MG? By … does wesley snipes do his own stunts